Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense is Issued U.S. Patent for Inflammation Imaging Product

February 1, 2016 - Pittsburgh, Pennsylvania

Celsense, Inc., announced today that it has received a Notice of Allowance for US Patent Application 13/901,663 with claims covering its inflammation imaging product, V-Sense.

V-Sense is a perfluorocarbon tracer agent used to label inflammatory cells after intravenous injection, particularly monocytes/macrophages. V-Sense makes these cells detectable in vivo using magnetic resonance imaging (MRI). V-Sense can be used to non-invasively image and quantify localized inflammation using MRI in a multitude of applications.

Data derived using V-Sense has appeared in over two dozen journal articles, authored by investigators in Europe and North America. Disease models using V-Sense have included, for example, neuropathic pain, tumor associated macrophages, multiple sclerosis, acute myocardial infarction, traumatic brain injury, organ transplant rejection, and IBD/Crohn’s.

“We are really excited to add this patent to our growing intellectual property portfolio and to extend our leadership position in cellular and molecular imaging tools,” said Charlie O’Hanlon, President and CEO of Celsense.

V-Sense is currently available for use in preclinical research. Multiple formulations of V-Sense are available, including ‘dual-mode’ composite versions containing the MRI agent and fluorescent dyes. These dyes enable detection by fluorescent microscopy, in vivo fluorescence imaging, and flow cytometry.

The patent, “Compositions and methods for producing emulsions for nuclear magnetic resonance and other applications,” includes claims covering compositions for the use of perfluorocarbon tracer agents to detect the accumulation of leukocytes using MRI and nuclear magnetic resonance (NMR). V-Sense was invented by scientists Dr. Jelena M. Janjic and Dr. Eric T. Ahrens.

About Celsense, Inc.
Celsense, Inc. develops and markets novel products that enable the non-invasive imaging of populations of cells using in vivo using MRI. Customers include leading pharmaceutical and biotechnology companies and medical research centers worldwide. Celsense’s mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com